Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

The Lancet Oncology

Volumn 17, Issue 11, 2016, Pages 1533-1542

  Reijneveld, Jaap C ^a   Taphoorn, Martin J B ^c   Coens, Corneel ^d   Bromberg, Jacoline E C ^e   Mason, Warren P ^f   Hoang Xuan, Khê ^g   Ryan, Gail ^h   Hassel, Mohamed Ben ⁱ   Enting, Roelien H ^j   Brandes, Alba A ^k   Wick, Antje ^l   Chinot, Olivier ^m   Reni, Michele ⁿ   Kantor, Guy ^o,p   Thiessen, Brian ^q   Klein, Martin ^b   Verger, Eugenie ^r   Borchers, Christian ^s,t   Hau, Peter ^u   Back, Michael ^v   Smits, Anja ^w   Golfinopoulos, Vassilis ^d   Gorlia, Thierry ^d   Bottomley, Andrew ^d   Stupp, Roger ^x   Baumert, Brigitta G ^y,z,aa   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d EORTC DATA CENTER   (Belgium)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF TORONTO   (Canada)

^g SORBONNE UNIVERSITÉ   (France)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ CENTRE EUGÈNE MARQUIS   (France)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m AIX MARSEILLE UNIVERSITY   (France)

ⁿ SAN RAFFAELE HOSPITAL   (Italy)

^o INSTITUT BERGONIÉ   (France)

^p UNIVERSITÉ DE BORDEAUX   (France)

^q BRITISH COLUMBIA CANCER AGENCY   (Canada)

^r HOSPITAL CLÍNIC   (Spain)

^s UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^t Department of Neurosurgery Hauptstrae   (Germany)

^u UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^v ROYAL NORTH SHORE HOSPITAL   (Australia)

^w UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^x LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^y UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^z MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^aa UNIVERSITY OF BONN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; DACARBAZINE;

ADULT; ALOPECIA; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COGNITION ASSESSMENT; COMPARATIVE EFFECTIVENESS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEARING IMPAIRMENT; HIGH RISK PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TASTE DISORDER; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER GRADING; CLINICAL TRIAL; GLIOMA; MORTALITY; MULTICENTER STUDY; PSYCHOLOGY;

BRAIN NEOPLASMS; DACARBAZINE; GLIOMA; HUMANS; NEOPLASM GRADING; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 84995543012     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30305-9     Document Type: Article

References (42)

1. 1 Soffietti, R, Baumert, BG, Bello, L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17 (2010), 1124–1133.
2. 2 van den Bent, MJ, Afra, D, de Witte, O, et al., for the EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366 (2005), 985–990.
3. 3 Douw, L, Klein, M, Fagel, SSAA, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8 (2009), 810–818.
4. 4 Brada, M, Viviers, L, Abson, C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14 (2003), 1715–1721.
5. 5 Quinn, JA, Reardon, DA, Friedman, AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21 (2003), 646–651.
6. 6 Hoang-Xuan, K, Capelle, L, Kujas, M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22 (2004), 3133–3138.
7. 7 Baumert, BG, Hegi, ME, van den Bent, MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol, 2016 published online Sept 26. http://dx.doi.org/10.1016/S1470-2045(16)30313-8.
8. 8 Dirven, L, Reijneveld, JC, Aaronson, NK, Bottomley, A, Uitdehaag, BM, Taphoorn, MJ, Health-related quality of life in patients with brain tumors: limitations and additional outcome measures. Curr Neurol Neurosci Rep, 13, 2013, 359.
9. 9 Taphoorn, MJ, Sizoo, EM, Bottomley, A, Review on quality of life issues in patients with primary brain tumors. Oncologist 15 (2010), 618–626.
10. 10 Reijneveld, JC, Sitskoorn, MM, Klein, M, Nuyen, J, Taphoorn, MJ, Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology 56 (2001), 618–623.
11. 11 Aaronson, NK, Taphoorn, MJ, Heimans, JJ, et al. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol 29 (2011), 4430–4435.
12. 12 Pignatti, F, van den Bent, M, Curran, D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20 (2002), 2076–2084.
13. 13 Tolcher, AW, Gerson, SL, Denis, L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 (2003), 1004–1011.
14. 14 Young, T, Haes, H, Fayers, P, et al. Guidelines for assessing quality of life in clinical trials, 1999, EORTC Quality of Life Group, Brussels.
15. 15 Karim, ABMF, Maat, B, Hatlevoll, R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36 (1996), 549–556.
16. 16 Shaw, E, Arusell, R, Scheithauer, B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20 (2002), 2267–2276.
17. 17 Cull, A, Sprangers, MA, Bjordal, K, Aaronson, NK, West, K, Bottomley, A, Guidelines for translating EORTC questionnaires, 2002, EORTC Quality of Life Group, Brussels.
18. 18 Aaronson, NK, Ahmedzai, S, Bergman, B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
19. 19 Taphoorn, MJ, Claassens, L, Aaronson, NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46 (2010), 1033–1040.
20. 20 Fayers, P, Aaronson, NK, Bjordal, K, Groenvold, M, Curran, D, Bottomley, A, EORTC QLQC-30 scoring manual, 3rd edn., 2001, EORTC Quality of Life Group, Brussels.
21. 21 Efficace, F, Bottomley, A, Osoba, D, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 21 (2003), 3502–3511.
22. 22 Folstein, MF, Folstein, SE, McHugh, PR, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
23. 23 Brown, PD, Buckner, JC, O'Fallon, JR, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein mini-mental state examination. J Clin Oncol 21 (2003), 2519–2524.
24. 24 Fayers, P, Weeden, S, Curran, D, EORTC QLQ-C30 reference values, 1998, EORTC, Brussels.
25. 25 Osoba, D, Rodrigues, G, Myles, J, Zee, B, Pater, J, Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998), 139–144.
26. 26 King, MT, The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5 (1996), 555–567.
27. 27 van de Poll-Franse, LV, Mols, F, Gundy, CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47 (2011), 667–675.
28. 28 Boele, FW, Douw, L, Reijneveld, JC, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. J Clin Oncol 33 (2015), 1023–1029.
29. 29 Kiebert, GM, Curran, D, Aaronson, NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). Eur J Cancer 34 (1998), 1902–1909.
30. 30 Liu, R, Solheim, K, Polley, MY, et al. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol 11 (2009), 59–68.
31. 31 Taphoorn, MJ, Stupp, R, Coens, C, et al. for the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumour Group EORTC Radiotherapy Group, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6 (2005), 937–944.
32. 32 Armstrong, TS, Wefel, JS, Wang, M, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 31 (2013), 4076–4084.
33. 33 Taphoorn, MJ, van den Bent, MJ, Mauer, ME, et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 25 (2007), 5723–5730.
34. 34 Walker, M, Brown, J, Brown, K, Gregor, A, Whittle, IR, Grant, R, Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol 63 (2003), 179–186.
35. 35 Vordermark, D, Avoiding bias in the prospective evaluation of patients with brain metastases. J Clin Oncol 25 (2007), 4023–4025.
36. 36 Reijneveld, JC, Klein, M, Taphoorn, MJ, Postma, TJ, Heimans, JJ, Improved, personalized treatment of glioma necessitates long-term follow-up of cognitive functioning. Pharmacogenomics 13 (2012), 1667–1669.
37. 37 Cocks, K, King, MT, Velikova, G, Fayers, PM, Brown, JM, Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 44 (2008), 1793–1798.
38. 38 Maringwa, J, Quinten, C, King, M, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 22 (2011), 2107–2112.
39. 39 Buckner, JC, Shaw, EG, Pugh, SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374 (2016), 1344–1355.
40. 40 Habets, EJ, Taphoorn, MJ, Nederend, S, et al. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J Neurooncol 116 (2014), 161–168.
41. 41 Klein, M, Heimans, JJ, Aaronson, NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360 (2002), 1361–1368.
42. 42 Taphoorn, MJ, Klein, M, Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3 (2004), 159–168.